Research programme: antibody-based cancer immunotherapeutics - For-Robin

Drug Profile

Research programme: antibody-based cancer immunotherapeutics - For-Robin

Alternative Names: hJAA-F11; JAA-F-11:DM1; JAA-F11; JAA-F11 antibody

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Buffalo
  • Developer For-Robin
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer

Most Recent Events

  • 24 Oct 2017 Antibody-based cancer immunotherapeutics - For-Robin is available for licensing as of 24 Oct 2017.
  • 24 Oct 2017 Pharmacodynamic results from a preclinical study in Breast cancer released by For-Robin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top